Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation

A1 Originalartikel i en vetenskaplig tidskrift (referentgranskad)


Interna författare/redaktörer


Publikationens författare: Strnad P, Siegel M, Toivola DM, Choi K, Kosek JC, Khosla C, Omary MB
Förläggare: WILEY
Publiceringsår: 2006
Tidskriftsakronym: FEBS LETT
Volym: 580
Nummer: 9
Artikelns första sida, sidnummer: 2351
Artikelns sista sida, sidnummer: 2357
Antal sidor: 7
ISSN: 1873-3468


Abstrakt

Mallory bodies (MBs) are characteristic of several liver disorders, and consist primarily of keratins with transglutaminase-generated keratin crosslinks. We tested the effect of the transglutaminase-2 (TG2) inhibitor KCC009 on MB formation in a mouse model fed 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC). KCC009 decreased DDC-induced liver enlargement without affecting NIB formation or extent of liver injury. TG2 protein and activity increased after DDC feeding and localized within and outside hepatocytes. KCC009 inhibited DDC-induced hepatomegaly by affecting hepatocyte cell size rather than proliferation. Hence, TG2 is a potential mediator of injury-induced hepatomegaly via modulation of hepatocyte hypertrophy, and KCC009-mediated TG2 inhibition does not affect mouse MB formation. (c) 2006 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.


Nyckelord

keratin, Mallory body, transglutaminase

Senast uppdaterad 2019-06-12 vid 05:45